

## Teladoc Health (USA): Merger with Livongo Health (USA)

### Changes in FTSE RAFI™ Index Series

27 October 2020

Subject to the completion of the Merger between Teladoc Health (USA, constituent) and Livongo Health (USA, constituent/non-constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI US 1500 Mid Small Index	30 October 2020
FTSE RAFI US 1500 Mid Small Index - QSR	30 October 2020

\*Based on the cash and stock merger terms of \$11.33 USD\*\* and 0.592 of a share of Teladoc Health per share of Livongo Health held.

\*\*Cash consideration consists of the cash terms of \$4.24 USD per share of Livongo Health held and special dividend payment by Livongo Health to Livongo Health shareholders of \$7.09 USD per share held.

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at [www.ftserussell.com](http://www.ftserussell.com)

[Terms of Use](#) | Copyright © 2020 FTSE Russell